Global Leading Market Research Publisher QYResearch announces the release of its latest report “Multiple Sclerosis Treatment Devices – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Multiple Sclerosis Treatment Devices market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Multiple Sclerosis Treatment Devices was estimated to be worth US3,024millionin2025andisprojectedtoreachUS3,024millionin2025andisprojectedtoreachUS5,984 million by 2032, growing at a robust CAGR of 10.4% from 2026 to 2032. In 2024, global production reached approximately 547,800 units, with an average global market price of approximately US$5,500 per unit. For neurologists, physical therapists, and MS (Multiple Sclerosis) patients, the core business imperative lies in deploying MS treatment devices that address the critical need for managing debilitating symptoms such as walking difficulties (gait impairment), muscle weakness, spasticity, fatigue, balance disorders, bladder dysfunction, and pain—thereby improving mobility, independence, and quality of life. Multiple Sclerosis treatment devices include electrical stimulation devices (functional electrical stimulation (FES) for foot drop (Bioness L300 Go, WalkAide), transcutaneous electrical nerve stimulation (TENS) for pain, neuromuscular electrical stimulation (NMES) for muscle strengthening), neurostimulation devices (spinal cord stimulation (SCS) for pain, deep brain stimulation (DBS) for tremor (not common), vagus nerve stimulation (VNS) (research)), and other assistive technologies (wearable exoskeletons (Ekso, Indego), robotic gait trainers (Lokomat (Hocoma)), mobility aids (walkers, canes), fall detection devices, smart watches (fall risk, activity monitoring), bladder stimulation (sacral neuromodulation InterStim)). Applications: hospitals and clinics (prescription, physical therapy, neurorehabilitation), ambulatory surgical centers (ASCs) (device implantation, e.g., SCS, baclofen pump), and home use (portable FES, TENS, mobility aids). Key suppliers: Medtronic (SCS), Hocoma (Lokomat robotic gait training), Bioness (FES now part of Bioventus?), Phillips-Medisize (drug delivery device manufacturing not primary), Ypsomed, Owen Mumford, SHL Medical (auto-injector devices (disease-modifying therapies (DMTs)) not symptom management but also MS treatment devices (but categorized). Invacare (mobility aids), Becton Dickinson (drug delivery). Gerresheimer (drug delivery).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/6093277/multiple-sclerosis-treatment-devices
The Multiple Sclerosis Treatment Devices market is segmented as below:
Ypsomed AG
Owen Mumford Ltd
SHL Medical AG
Phillips-Medisize
Becton, Dickinson and Company
Nemera
Gerresheimer AG
Medtronic plc
Invacare Corporation
Hocoma AG
Segment by Type
Electrical Stimulation Devices
Neurostimulation Devices
Others
Segment by Application
Hospitals and Clinics
Ambulatory Surgical Centers
Others
1. Market Drivers: Rising MS Prevalence, Symptom Management Demand, and Technological Advances
Several powerful forces are driving the MS treatment devices market:
Increasing MS prevalence (2.8 million globally) – Diagnosed MS (women 2:1). Onset age 20-50. Lifetime disease, progressive. Symptom management required for decades.
Gait impairment (foot drop) – 70-80% MS patients experience walking difficulty. FES devices (Bioness L300 Go, WalkAide, Odstock Dropped Foot Stimulator) stimulate peroneal nerve during swing phase (improve gait symmetry, reduce fall risk). Reimbursement.
Robotic rehabilitation and exoskeletons – Intense physical therapy improves mobility. Lokomat (Hocoma) robotic gait trainer, EksoNR exoskeleton for MS (limited). Neuroplasticity.
Recent market data (December 2025): According to Global Info Research analysis, electrical stimulation devices (FES, TENS, NMES) dominate with approximately 45% revenue share (non-invasive, home use, symptom relief). Neurostimulation devices (SCS, DBS) 30% share (implanted, chronic pain). Others (mobility aids, robotic trainers, auto-injectors) 25% share. Hospitals and clinics (physical therapy, neurorehab) largest application (50% share). Ambulatory surgical centers (implantation) 20% share. Others (home use, self-care) 30% share. North America largest market (45% share). Europe 30% share. Asia-Pacific 15% share (fastest-growing, 12-14% CAGR). Medtronic (Neurostimulation -Intrathecal Baclofen Pump, SCS) market leader (20-25% share). Hocoma (robotic gait). Bioness (FES). Ypsomed, Owen Mumford, SHL include auto-injector pens (interferon, glatiramer acetate) (disease modifying therapy (DMT) delivery).
2. Treatment Device Types and Specifications
| Type | Mechanism | Invasive | Indication | Typical Cost | Share |
|---|---|---|---|---|---|
| Electrical Stimulation (FES, TENS, NMES) | Electrical current to nerves/muscles | Non-invasive (surface electrodes) | Foot drop, pain, muscle strengthening | US$500-5,000 | ~45% |
| Neurostimulation (SCS, DBS, PNS) | Implanted electrode + pulse generator | Invasive (surgical) | Chronic pain, tremor (rare MS) | US$20,000-50,000 | ~30% |
| Others (Robotic, Mobility, Auto-injector) | Mechanical, motorized | Non-invasive | Gait training, walking aid, drug delivery | US$1,000-100,000 | ~25% |
Key specifications: FES gait sensor (heel switch, accelerometer). Stimulation parameters (pulse width 50-300µs, frequency 20-40Hz, amplitude 0-100mA). Neurostimulator (rechargeable vs non-rechargeable, MRI conditional). Auto-injector (pre-filled syringe, needle safety, dose setting (0.25-1mL)). Wearable exoskeleton (hip, knee actuation, battery life 2-4 hours). Fall detection (accelerometer, gyroscope). Smartwatch (heart rate, oxygen saturation).
Exclusive observation (Global Info Research analysis): MS treatment devices market is segmented into disease-modifying therapy (DMT) delivery devices (auto-injectors, pen injectors) and symptom management devices (FES, SCS, robotics). Ypsomed, Owen Mumford, SHL Medical, Phillips-Medisize, BD, Nemera, Gerresheimer manufacture auto-injector platforms for pharma (Biogen, Novartis, Merck, Roche, Sanofi). Symptom management (Medtronic, Bioness, Hocoma, Invacare). Auto-injector market driven by subcutaneous DMTs (interferon beta, glatiramer acetate, natalizumab (Tysabri), ocrelizumab (Ocrevus)). DMT market >> symptom devices.
User case – foot drop (December 2025): MS patient (relapsing-remitting, 40-year-old) prescribed Bioness L300 Go (FES). Cuff around calf, electrode over peroneal nerve, foot sensor (heel switch). Stimulates during gait swing phase. Reduced falls, improved walking confidence.
User case – intrathecal baclofen pump (January 2026): Severe spasticity (legs). Medtronic SynchroMed II pump implanted (abdominal wall), catheter to intrathecal space (spinal). Delivers baclofen continuously (reduces spasticity). Refill every 3-6 months. Cost US$30,000-50,000.
3. Technical Challenges
Reimbursement (CMS, private insurance) – FES devices (Bioness) not uniformly covered by Medicare (only specific codes). Out-of-pocket expense.
Implanted device complications (infection) – SCS, baclofen pump (surgical infection, lead migration, revision).
Technical difficulty – patient adherence to home therapy: FES requires daily use (compliance low). Wearable sensors (tracking).
Technical development (October 2025): Medtronic (US) received FDA approval for rechargeable implantable pulse generator (IPG) for SCS (10-year battery). MRI conditional 1.5T.
4. Competitive Landscape
Key players include: Ypsomed AG (Switzerland – auto-injector, pen injectors for DMT), Owen Mumford Ltd (UK – Auto-injector, safety pen), SHL Medical AG (Sweden – auto-injector, Molly), Phillips-Medisize (US – drug delivery device contract manufacturing), Becton, Dickinson and Company (US – auto-injector, pen needle), Nemera (France – auto-injector), Gerresheimer AG (Germany – auto-injector, syringe), Medtronic plc (US – neurostimulation, baclofen pump), Invacare Corporation (US – mobility aids), Hocoma AG (Switzerland – Lokomat). Medtronic, Bioness (not listed), Hocoma leaders.
Regional dynamics: North America (Medtronic, Becton Dickinson, Invacare ) largest. Europe (Ypsomed, Owen Mumford, SHL, Nemera, Gerresheimer, Hocoma). Auto-injector manufacturing outsourced to CDMOs (Contract Development and Manufacturing Organizations).
5. Outlook
Multiple sclerosis treatment devices market will grow at 10.4% CAGR to US$6.0 billion by 2032, driven by DMT self-injection devices (auto-injectors), FES (gait impairment), and neurostimulation (pain, spasticity). Technology trends: wearable FES (smart sensors), implantable rechargeable neurostimulators, and home-based robotic gait training (tele-rehabilitation). Asia-Pacific growth (12-14% CAGR). Symptom management devices (FES) and DMT delivery devices both growing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
